-transparent.png){kind=logo}
Twenty-seven patients in the chronic phase of a Philadelphia chromosome-positive chronic myelogenic leukemia (CML) underwent a monotherapy with recombinant interferon-alpha 2b (rIFN-alpha 2b), receiving a mean dose of 3 x 5 Mio. IU per week. Eight of the 27 patients developed both rIFN-alpha 2b-binding and -neutralizing antibodies during therapy. Sera of these patients abrogated both antiviral and antiproliferative activities of rIFN-alpha 2b, but not of nIFN-beta or rIFN gamma. Only one serum neutralized nIFN-alpha. The IFN binding and neutralizing titers rose during therapy, while a decrease occurred over months after cessation of therapy. The IgG fraction obtained by DEAE chromatography contained more than 90% of the IFN-neutralizing capacity of the purified sera. This result strongly suggested that IgG antibodies are responsible for the IFN-alpha-neutralizing activity.
P von Wussow, and
D Jakschies, and
M Freund, and
H Deicher
June 1993,
Acta neurologica Scandinavica,
P von Wussow, and
D Jakschies, and
M Freund, and
H Deicher
April 1988,
Lancet (London, England),
P von Wussow, and
D Jakschies, and
M Freund, and
H Deicher
January 1992,
Dermatology (Basel, Switzerland),
P von Wussow, and
D Jakschies, and
M Freund, and
H Deicher
October 1994,
British journal of cancer,
P von Wussow, and
D Jakschies, and
M Freund, and
H Deicher
December 1991,
Australian and New Zealand journal of medicine,
P von Wussow, and
D Jakschies, and
M Freund, and
H Deicher
November 1986,
The New England journal of medicine,
P von Wussow, and
D Jakschies, and
M Freund, and
H Deicher
September 2000,
Archivos espanoles de urologia,
P von Wussow, and
D Jakschies, and
M Freund, and
H Deicher
January 1996,
American journal of hematology,
P von Wussow, and
D Jakschies, and
M Freund, and
H Deicher
January 2015,
American journal of cancer research,
P von Wussow, and
D Jakschies, and
M Freund, and
H Deicher
August 1992,
European journal of haematology,
